突破性治疗药物-话题@MedSci

#突破性治疗药物#

9篇内容 | 993人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1300740, encodeId=39411300e40bb, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=复盘新冠时代，那些不得不说的突破性治疗药物, objectType=article, longId=299025, objectId=9a0f299025e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a0f299025e0, replyNumber=0, likeNumber=35, createdTime=2022-02-19, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a0f299025e0, moduleTitle=复盘新冠时代，那些不得不说的突破性治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a0f299025e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300739, encodeId=6fbe1300e3993, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=Mavacamten获中国“突破性治疗药物”认证，用于治疗梗阻性肥厚型心肌病, objectType=article, longId=298944, objectId=f5d829894405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d829894405, replyNumber=0, likeNumber=54, createdTime=2022-02-18, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d829894405, moduleTitle=Mavacamten获中国“突破性治疗药物”认证，用于治疗梗阻性肥厚型心肌病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d829894405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300738, encodeId=29361300e385f, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定, objectType=article, longId=213247, objectId=3f8321324e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8321324e7a, replyNumber=0, likeNumber=31, createdTime=2021-06-27, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8321324e7a, moduleTitle=勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8321324e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300737, encodeId=e3d81300e37f6, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=国产创新药迎来高光时刻！CAR-T疗法拟纳入突破性治疗药物名单, objectType=article, longId=198997, objectId=e1ad19899eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1ad19899eea, replyNumber=0, likeNumber=50, createdTime=2020-08-09, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1ad19899eea, moduleTitle=国产创新药迎来高光时刻！CAR-T疗法拟纳入突破性治疗药物名单, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1ad19899eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300736, encodeId=e8a01300e36bc, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=Y-mAbs在美国申请将抗GD2单抗naxitamab批准用作神经母细胞瘤的突破性治疗药物, objectType=article, longId=184091, objectId=ac6c18409105, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac6c18409105, replyNumber=0, likeNumber=39, createdTime=2019-12-05, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac6c18409105, moduleTitle=Y-mAbs在美国申请将抗GD2单抗naxitamab批准用作神经母细胞瘤的突破性治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac6c18409105)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300735, encodeId=66371300e35f3, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=CDE发布了《突破性治疗药物工作程序》和《优先审评审批工作程序》征求意见, objectType=article, longId=182785, objectId=de68182e85f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de68182e85f1, replyNumber=0, likeNumber=34, createdTime=2019-11-11, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de68182e85f1, moduleTitle=CDE发布了《突破性治疗药物工作程序》和《优先审评审批工作程序》征求意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de68182e85f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300734, encodeId=5abf1300e348a, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格, objectType=article, longId=38021, objectId=0ab338021cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ab338021cd, replyNumber=0, likeNumber=35, createdTime=2014-07-20, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ab338021cd, moduleTitle=勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ab338021cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300733, encodeId=91fc1300e33db, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=GSK旗下肺癌药物Tafinlar获FDA突破性治疗药物资格, objectType=article, longId=29493, objectId=6fb1294934e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb1294934e, replyNumber=0, likeNumber=35, createdTime=2014-01-18, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb1294934e, moduleTitle=GSK旗下肺癌药物Tafinlar获FDA突破性治疗药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb1294934e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1300732, encodeId=de971300e3248, content=<a href='/topic/show?id=6a14e55375c' target=_blank style='color:#2F92EE;'>#突破性治疗药物#</a>, objectTitle=雅培生命旗下丙肝复方药物获FDA突破性治疗药物资格, objectType=article, longId=18518, objectId=baf818518d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baf818518d1, replyNumber=0, likeNumber=25, createdTime=2013-05-11, rootId=0, userName=xiaoshitou, userId=0357291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baf818518d1, moduleTitle=雅培生命旗下丙肝复方药物获FDA突破性治疗药物资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baf818518d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突破性治疗药物

2020-05-29

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

复盘新冠时代，那些不得不说的突破性治疗药物

2022-02-19

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

Mavacamten获中国“突破性治疗药物”认证，用于治疗梗阻性肥厚型心肌病

2022-02-18

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定

2021-06-27

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

国产创新药迎来高光时刻！CAR-T疗法拟纳入突破性治疗药物名单

2020-08-09

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

Y-mAbs在美国申请将抗GD2单抗naxitamab批准用作神经母细胞瘤的突破性治疗药物

2019-12-05

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

CDE发布了《突破性治疗药物工作程序》和《优先审评审批工作程序》征求意见

2019-11-11

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

勃林格肺纤维化药物Nintedanib获FDA突破性治疗药物资格

2014-07-20

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

GSK旗下肺癌药物Tafinlar获FDA突破性治疗药物资格

2014-01-18

xiaoshitou (审核中...)

前往app查看评论内容

#突破性治疗药物#

雅培生命旗下丙肝复方药物获FDA突破性治疗药物资格

2013-05-11

科室
- - 订阅+
  - 更多科室
工具
服务